Nancy Ryerson

Nancy Ryerson is a digital communicator with years of experience covering healthcare. Today, she's a Digital Marketing Manager at Antidote, where she manages the company's content marketing and SEO strategies. Prior to joining Antidote, Nancy spent three years at The Michael J. Fox Foundation, where she created content for Parkinson's disease patients and expanded the Foundation's email list by 100,000+ members in two years through search and social strategies. She holds a BA in English and journalism from NYU.

Find me on:

Clinical Trial Recruitment Tools for the 21st Century

Today, study teams have a variety of clinical trial recruitment tools at their disposal to find the right patients for their studies. As anyone involved in the patient recruitment process knows, enrolling patients into studies isn't a one-size-fits-all solution. Complex protocols in particular can make recruiting patients particularly challenging – and make using a varied approach more important.

Continue reading

5 Lesser-Known Reasons to Join Asthma Clinical Trials

If you live with asthma, you may still have trouble with symptoms even on your regular medication. That’s why asthma clinical trials explore new potential treatments for asthma.

Continue reading

What’s It Like to Participate in a Clinical Trial?

Do you know anyone who has participated in a clinical trial? It's very possible the answer is no. Studies show that patients are interested in participating, but don't often hear about opportunities to take part.

Continue reading

How to Advertise Different Types of Clinical Trials

Prior research on patient interest in clinical trials has tended to focus on studies as a monolith. At Antidote, we were curious whether the type of trial – observational, interventional, etc. – made a difference in terms of patient interest.

Continue reading

Living with PBC: 5 Tips That Can Help

Looking back, Carol Roberts believes she experienced the fatigue associated with primary biliary cholangitis, or PBC, years before her diagnosis.

Continue reading

Asthma and Allergy Advocates Gather in Washington, D.C. to Share Resources and Join Forces

Running a successful health advocacy blog means being social online, but the day-to-day work of writing and posting can feel lonely. On May 7, the Asthma & Allergy Network brought together online influencers for a chance to swap stories and resources in person at the AAN Influencers Summit. The next day, they advocated for allergy and asthma research priorities on Capitol Hill.

Continue reading

What’s the Latest Research on Asthma and Allergies?

May is Asthma and Allergy Awareness Month. Today, more than 26 million Americans live with asthma – and every day, 10 Americans die from asthma. Worldwide, up to 30% of people have allergic rhinitis, or hay fever. Chances are, you or someone you know has allergies or asthma – you might even be suffering from seasonal or year-round allergies as you read this.

Continue reading

What’s the Latest Research on Idiopathic Pulmonary Fibrosis?

Idiopathic Pulmonary Fibrosis (IPF) is a rare, difficult-to-treat lung disease affecting around 100,000 patients in the U.S. While two medications have been approved to slow IPF progression, there are currently no approved treatments that can stop or reverse the disease.

Continue reading

Advertising Clinical Trials: What Works in 2019

There are more approaches to advertising clinical trials than ever before, from digital advertising, to site databases, to sharing materials in doctors' offices. Unfortunately, trial protocols have become more complex at the same time outreach options have expanded. Despite the best efforts of the industry, 73% of Americans don't even know anyone who has participated in a trial, let alone joined ...

Continue reading

After a Surprise Kidney Disease Diagnosis, This Patient Turned to Education and Advocacy

Patrick Gee didn't know that there were any problems with his kidneys until a doctor diagnosed him with kidney failure. Years on dialysis, four surgeries, 47 days in the hospital, and one successful kidney transplant later, he's participated in two clinical trials and become a proud advocate for the American Kidney Fund.

Continue reading

Get our latest posts in your inbox